8-K - BIXT - Equibles

UNITED

STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

BIOXYTRAN,

INC.

(Exact Name if Business Issuer as specified in its Charter)

Nevada	001-35027	26-2797630
(State or other Jurisdiction<br><br> of Incorporation)	(Commission File<br> Number)	(IRS Employer<br><br> Identification Number)

75, Second Avenue,

Suite 605

Needham MA, 02494

(Address of principal executive offices, including zip code)

(617) 494-1199

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425<br> under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 1 4a- 12<br> under the Exchange Act (17 CFR 240.1 4a- 12)
---	---
☐	Pre-commencement communications pursuant to<br> Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))
---	---
☐	Pre-commencement communications pursuant to<br> Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))
---	---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BIXT	OTC Pink

Item8.01 Other Events.

On May 12^th^, 2022, the International Bureau of the Patent Cooperation Treaty (PCT) approved and published two patent applications from Bioxytran, Inc.:

●	WO<br> 2022/099061 - Polysaccharides for Use in Treating Sars-Cov-2 Infections - The invention<br> provides a method for treating SARS-CoV-2 by administering an effective amount of galactomannans<br> to a subject in need thereof.
●	WO2022/099061<br> - Polysaccharides for IV Administration that Treat Sars-Cov-2 Infections - The invention<br> provides a method for treating SARS-CoV-2 by administering an effective amount of pectin<br> polysaccharides to a subject in need thereof.
---	---

On June 8, 2022 United States Patent and Trademark Office (USPTO) approved the Trademark ProLectin to be published in the published in the Trademark Official Gazette (TMOG) on June 28, 2022.

Item9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit
Number	Description
10.69	Approval of International Patent WO2022/099052 - Polysaccharides for Use in Treating Sars-Cov-2 Infections, dated May 12, 2022.
10.70	Approval of International Patent WO2022/099061 - Polysaccharides for IV Administration that Treat SARS-CoV-2 Infections, dated May 12, 2022.
10.71	Official USPTO Notice of Publication under 12(A) for the Trademark ProLectin

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:	/s/ David Platt
Name:	Dr. David Platt
Title:	President and Chief Executive Officer
Dated: <br>June 10, 2022

Exhibit 10.69

PATENT COOPERATION TREATY WO 2022/099052 PCT/US2021/058310 From the INTERNATIONAL BUREAU PCT To: NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION MCDONALD, J. Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant’s or agent’s file reference 51577-002WO2 IMPORTANT NOTICE International application No. PCT/US2021/058310 International filing date (day/month/year) 05 November 2021 (05.11.2021) Priority date (day/month/year) 06 November 2020 (06.11.2020) Applicant BIOXYTRAN, INC. The applicant is hereby notified that the International Bureau: ☒ has published the above-indicated international application on 12 May 2022 (12.05.2022) under No. WO 2022/099052 □ has republished the above-indicated international application on under No. WO For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the published international application. - A copy of the international application is available for viewing and downloading on WIPO’s website at the following address: https://patentscope.wipo.int/ (in the appropriate field of the structured search, enter the PCT or WO number). - The applicant may also obtain a paper copy of the published international application from the International Bureau by sending an e-mail to patentscope@wipo.int or by submitting a written request to the contact details provided below. Warning: Following publication of the international application, applicants, agents and inventors may receive misleading requests for payment of fees that appear to come from the International Bureau of WIPO or other patent Offices which are unrelated to the processing of international applications under the PCT. Agents are particularly encouraged to be vigilant and alert their clients about this practice. Examples of such requests for payment which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm. Please forward copies of any such requests to pct.legal@wipo.int. The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer Xin Wang e-mail pct.team2@wipo.int Telephone No. +41 22 338 74 02 FormPCT/IB/311 (revised January 2020)

Exhibit 10.70

(GRAPHIC)

WO 2022/099061 PCT/US2021/058321 PATENT COOPERATION TREATY From the INTERNATIONAL BUREAU PCT NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION To: MCDONALD,J., Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant’s or agent’s file reference 51577-003W02 IMPORTANT NOTICE International application No. PCT/US2021/058321International filing date (day/month/year) 05 November 2021 (05.11.2021) Priority date (day/month/year) 06 November 2020 (06.11.2020) Applicant BIOXYTRAN, INC. The applicant is hereby notified that the International Bureau: has published the above-indicated international application on 12 May 2022 (12.05.2022) under No. WO 2022/099061 □ has republished the above-indicated international application on under No. WO For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the published international application. - A copy of the international application is available for viewing and downloading on WIPO’s website at the following address: https://patentscope.wipo.int/ (in the appropriate field of the structured search, enter the PCT or WO number). - The applicant may also obtain a paper copy of the published international application from the International Bureau by sending an e-mail to patentscope@wipo.int or by submitting a written request to the contact details provided below. Warning: Following publication of the international application, applicants, agents and inventors may receive misleading requests for payment of fees that appear to come from the International Bureau of WIPO or other patent Offices which are unrelated to the processing of international applications under the PCT. Agents are particularly encouraged to be vigilant and alert their clients about this practice. Examples of such requests for payment which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm. Please forward copies of any such requests to pct.legal@wipo.int. The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer Xiaofan Tang e-mail pct.team2@wipo.int Telephone No. +41 22 338 74 02 Form PCT/IB/311 (revised January 2020)

Exhibit 10.71

UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)

Commissioner for Trademarks

www.uspto.gov

OFFICIAL USPTO NOTICE OF PUBLICATION UNDER 12(a)

U.S. Application Serial No. 90888912

Mark: PROLECTIN

International Class(es): 005

Owner: Pharmalectin, Inc.

Docket/Reference No. 51577-T02001

Issue Date: June 8, 2022

Your mark is scheduled to publish in the Trademark OfficialGazette (TMOG) on June 28, 2022.

Your mark appears to be entitled to register on the Principal Register upon the acceptance of a statement of use, subject to any claims of concurrent use.

What happens when your mark publishes. Within 30 days of the publication date, any party who believes it will be damaged by the registration of the mark may file a notice of opposition (or extension of time) with the Trademark Trial and Appeal Board. If no objection is filed, we will issue a Notice of allowance.

View your mark in the TMOG after the publication date at https://tmog.uspto.gov/ by selecting your publication date in the “issues” field, entering your serial number in the “search by” field, and clicking on the magnifying glass.

Ensure that the information in the TMOG is correct. If any information is incorrect, promptly request correction using the “Post-Approval/Publication/Post-Notice of Allowance (NOA) Amendment” form at https://teas.uspto.gov/office/ppa/. For more information, see https://www.uspto.gov/trademark/trademark-updates-andannouncements/procedures-submitting-amendmentscorrections-trademark.

Direct questions about this notice to the Trademark Assistance Center (TAC)at 1-800-786-9199 (select option 1) or TrademarkAssistanceCenter@uspto.gov.

Email Address(es):

cedocket@clarkelbing.com